Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Next Previous
Trial Profile

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PACCT-1; TAILORx

    • Most Recent Events

    • 06 Dec 2022 According to EXACT Sciences Corporation media release, data from this study will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
    • 01 Apr 2021 Results of retrospective analysis assessing insurance status and residence zip code correlation with early discontinuation of endocrine therapypublished in the Cancer
    • 31 May 2020 Results (n=9475) assessing association between study entry insurance status and adherence to endocrine therapy, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top